Welcome to our dedicated page for Reneo Pharmaceuticals SEC filings (Ticker: RPHM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RPHM SEC filings page on Stock Titan provides access to the regulatory record associated with Reneo Pharmaceuticals, Inc. and its subsequent transformation into OnKure Therapeutics, Inc. These filings trace the company’s evolution from a pharmaceutical issuer historically focused on rare genetic mitochondrial diseases to the public entity for a precision oncology business under the OnKure name and the OKUR ticker.
Historical Reneo filings include periodic reports and disclosures that describe its focus on therapies for patients with rare genetic mitochondrial diseases, such as primary mitochondrial myopathies (PMM), and its development of mavodelpar (REN001), a potent and selective PPARδ agonist. Investors can use these documents to understand the company’s former research programs, clinical strategy, and financial position leading up to the suspension of mavodelpar development and the initiation of a strategic alternatives process.
Later filings detail the merger with OnKure, Inc., including the registration statement and proxy materials referenced in company news releases. These documents explain the structure of the all-stock transaction, expected ownership percentages, conditions to closing, and the planned name and ticker change to OnKure Therapeutics, Inc. (OKUR). Post-merger, current reports on Form 8-K reference OnKure Therapeutics, Inc. as the registrant and note that Reneo Pharmaceuticals is a former name, reflecting the completed corporate transition.
On Stock Titan, users can review these SEC filings alongside AI-powered tools that help summarize lengthy documents and highlight key items such as business descriptions, risk factors, and material events. For the historical RPHM symbol, this page serves as a regulatory archive, while ongoing filings for the operating precision oncology company appear under the OnKure Therapeutics, Inc. name and the OKUR ticker.
OnKure Therapeutics, Inc. received a joint Schedule 13G/A reporting that the named reporting persons — Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju — do not beneficially own any shares of the issuer's Class A common stock as of the reporting date. The filers state Delaware and U.S. organizational details and expressly disclaim status as a group. The filing confirms 0.0% ownership and shows no sole or shared voting or dispositive power for each reporting person, indicating they hold no economic or voting stake in the class disclosed.
OnKure Therapeutics, Inc. Schedule 13G/A filed by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. states that none of the Reporting Persons beneficially own any shares of OnKure common stock (CUSIP 68277Q105). The cover pages show 0 shares and 0% of the class for Perceptive Advisors, Mr. Edelman and the Master Fund, with zero sole or shared voting and dispositive power reported.
The filing confirms the Reporting Persons do not hold securities to influence control of the issuer and includes signatures by Joseph Edelman dated 08/14/2025. The issuer's principal executive office is listed in Boulder, Colorado.
Highbridge Capital Management, LLC reports holding 663,607 shares of OnKure Therapeutics, Inc. Class A Common Stock, representing 5.2% of the class based on 12,823,872 shares outstanding as of May 5, 2025. The shares are directly held by funds and accounts advised by Highbridge and Highbridge states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The Reporting Person is organized in Delaware with its principal business office at 277 Park Avenue, 23rd Floor, New York, NY, and the issuer’s principal executive offices are listed in Boulder, Colorado. The filing is signed by Kirk Rule, Executive Director, dated 08/14/2025.
Cantor Fitzgerald entities reported beneficial ownership of 669,539 shares of OnKure Therapeutics, Inc. Class A Common Stock, representing 5.2% of the outstanding shares. The percentage is calculated using 12,823,872 shares outstanding as of May 5, 2025. The filing lists four related reporting persons (Cantor Fitzgerald & Co., Cantor Fitzgerald Securities, Cantor Fitzgerald, L.P., and CF Group Management, Inc.) that together may be deemed to beneficially own the reported shares through shared voting and dispositive power, with shared voting power and shared dispositive power of 669,539 and no sole voting or dispositive power. The filing notes a related transaction in which Howard W. Lutnick agreed to divest certain interests and agreements were entered May 16, 2025 to transfer voting shares of CF Group Management to trusts controlled by Brandon G. Lutnick; those closings remain subject to customary conditions and regulatory approvals. The statement is certified and signed by authorized officers on August 14, 2025.
OnKure Therapeutics, Inc. reported interim financials for the quarter ended June 30, 2025 reflecting operations of the combined company after a reverse recapitalization with Reneo. The company had $83.4 million in cash and cash equivalents and an accumulated deficit of $186.0 million. Management states cash is sufficient to fund the current operating plan for at least the next 12 months.
Operating results show continuing investment in drug development: R&D expense was $12.6 million in the quarter and $25.6 million for the six months, driving a six-month net loss of $31.3 million. R&D increases were driven by higher clinical trial and manufacturing costs. The company completed a $65.0 million concurrent financing at closing of the Merger and is advancing its lead candidate, OKI-219, in a Phase 1a/1b trial. The filing discloses two plaintiff complaints related to the Merger and notes the Company continues to evaluate macroeconomic and legislative tax changes.
OnKure Therapeutics, Inc. announced that it issued a press release reporting its financial results for the quarter ended June 30, 2025. The company attached that press release as Exhibit 99.1 to this Current Report and described the release as reporting second-quarter financial results and providing a business update.
The report states that the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished, not filed, and therefore is not subject to the liabilities of being "filed" under the Exchange Act. The filing also shows that OnKure's Class A common stock trades as OKUR on The Nasdaq Stock Market and that the company is identified as an emerging growth company.
FAQ
What is the current stock price of Reneo Pharmaceuticals (RPHM)?
What is the market cap of Reneo Pharmaceuticals (RPHM)?
